UBS Group
ALXN

UBS Group’s Alexion Pharmaceuticals ALXN Stock Holding History

UBS Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-451,615
Closed -$83M – 10776
2021
Q2 		$83M Buy
451,615
+129,976
+40% +$22.3M 0.03% 593
2021
Q1 		$49.2M Buy
321,639
+206,093
+178% +$31.9M 0.02% 850
2020
Q4 		$18.1M Sell
115,546
-759,985
-87% -$97.7M 0.01% 1407
2020
Q3 		$100M Buy
875,531
+416,889
+91% +$45M 0.04% 396
2020
Q2 		$51.5M Sell
458,642
-207,113
-31% -$22M 0.02% 590
2020
Q1 		$59.8M Sell
665,755
-668,638
-50% -$65.6M 0.03% 480
2019
Q4 		$144M Buy
1,334,393
+746,516
+127% +$79.8M 0.05% 339
2019
Q3 		$57.6M Buy
587,877
+333,696
+131% +$37.6M 0.02% 615
2019
Q2 		$33.3M Buy
254,181
+17,371
+7% +$2.24M 0.01% 898
2019
Q1 		$32M Sell
236,810
-6,103
-3% -$759K 0.01% 870
2018
Q4 		$23.6M Sell
242,913
-129,516
-35% -$15.3M 0.01% 970
2018
Q3 		$51.8M Buy
372,429
+110,923
+42% +$13.9M 0.02% 658
2018
Q2 		$32.5M Sell
261,506
-366,873
-58% -$42.9M 0.01% 899
2018
Q1 		$70M Sell
628,379
-151,629
-19% -$18.1M 0.03% 500
2017
Q4 		$93.3M Buy
780,008
+319,853
+70% +$39M 0.04% 431
2017
Q3 		$64.6M Buy
460,155
+59,551
+15% +$8.09M 0.03% 505
2017
Q2 		$48.7M Buy
400,604
+342,732
+592% +$39.9M 0.03% 572
2017
Q1 		$7.02M Sell
57,872
-92,889
-62% -$12M ﹤0.01% 1788
2016
Q4 		$18.4M Buy
150,761
+97,824
+185% +$12M 0.01% 1076
2016
Q3 		$6.49M Sell
52,937
-40,530
-43% -$5.22M ﹤0.01% 1793
2016
Q2 		$10.9M Sell
93,467
-3,234
-3% -$459K 0.01% 1321
2016
Q1 		$13.5M Sell
96,701
-145,192
-60% -$21.3M 0.01% 1133
2015
Q4 		$46.1M Buy
241,893
+135,541
+127% +$23.7M 0.03% 532
2015
Q3 		$16.6M Sell
106,352
-35,573
-25% -$6.49M 0.01% 1018
2015
Q2 		$25.7M Sell
141,925
-70,524
-33% -$12.2M 0.02% 826
2015
Q1 		$36.8M Sell
212,449
-28,846
-12% -$5.22M 0.03% 631
2014
Q4 		$44.6M Buy
+241,295
New +$44.7M 0.03% 584

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ALXN Position: Q3 2021 in Review

UBS Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 451,615 shares — an estimated $83M sold.

UBS Group first reported a position in ALXN in Q4 2014 and held it in 27 quarters. The position peaked at $144M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • UBS Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 451,615 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83M.
  • UBS Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 27 quarters.
  • UBS Group's Alexion Pharmaceuticals position peaked at $144M in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.